In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data to predict human efavirenz exposure after single and continuous dosing as well as the effects of concomitant rifampicin and further to evaluate the weight-based dosage recommendations used to counteract the rifampicin–efavirenz interaction. Efavirenz pharmacokinetics were simulated using a physiologically based […]

Read More
Learn More